Repeated Occurrences of Basal Cell Cancer in Patients With Inflammatory Bowel Disease Treated With Immunosuppressive Medications

2020 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Nabeel Khan ◽  
Dhruvan Patel ◽  
Chinmay Trivedi ◽  
Himanshu Kavani ◽  
Elina Medvedeva ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Basal Cell ◽  
Bowel Disease ◽  
Cell Cancer ◽  
Basal Cell Cancer ◽  
Immunosuppressive Medications ◽  
Inflammatory Bowel

Effectiveness of Conjugate and Polysaccharide Pneumococcal Vaccines for Prevention of Severe Pneumococcal Disease Among Inflammatory Bowel Disease Patients

2021 ◽  
Author(s):  
Bryan L Love ◽  
Christopher J Finney ◽  
Jill K J Gaidos
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pneumococcal Disease ◽  
Pneumococcal Vaccination ◽  
Cox Proportional Hazards Model ◽  
Health Administration ◽  
Immunosuppressive Medications ◽  
Increased Risk ◽  
Inflammatory Bowel ◽  
The Impact

Abstract Background Streptococcus pneumoniae is an important pathogen responsible for severe pneumococcal diseases, including pneumonia, bacteremia/sepsis, and meningitis. Inflammatory bowel disease (IBD) patients have an increased risk for infections due to an altered immune system and treatment with immunosuppressive medications. The aim of this study was to assess the prevalence of severe pneumococcal disease (SPD) and evaluate the impact of pneumococcal vaccination on the risk of SPD in Veterans with IBD. Methods Subjects with IBD and SPD were identified from the VA Health Administration database using ICD9/10 codes. Pneumococcal vaccination and use of immunosuppressant medications were collected. Risk of SPD was evaluated using an adjusted Cox proportional hazards model controlling for demographics, medications, vaccination, and comorbidities. Results A total of 1798 cases of SPD were identified (283 pneumonia, 1,513 bacteremia, and 2 meningitis). SPD patients were older (60.9 years vs 59.4 years; p<0.001), had more comorbidities (Charlson Comorbidity Index of 2.11 vs. 0.96; p<0.001) and had increased mortality (4.6% vs. 1.5%, p<0.001). The risk of SPD was increased in Crohn’s disease (HR 1.15; 95% CI 1.05-1.27) and with more comorbidities (HR 1.45; 95% CI 1.42-1.48). Use of immunosuppressive medications increased the risk of SPD. Receipt of PCV13 either alone or in combination with PPSV23 predicted a five-fold decreased risk of SPD compared with no vaccination. Conclusion Vaccination with PCV13 alone or in combination with PPSV23 and revaccination with PPSV23, was protective against SPD. All IBD patients should be evaluated for pneumococcal vaccination, particularly those receiving or expected to receive immunosuppressive therapies.

Identification of genetic loci for basal cell nevus syndrome and inflammatory bowel disease in a single large pedigree

2006 ◽  
Vol 120 (1) ◽  
pp. 31-41 ◽  
Author(s):  
Carolien I. Panhuysen ◽  
Amir Karban ◽  
Alisa Knodle Manning ◽  
Theodore M. Bayless ◽  
Richard H. Duerr ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Basal Cell ◽  
Bowel Disease ◽  
Genetic Loci ◽  
Large Pedigree ◽  
Basal Cell Nevus Syndrome ◽  
Inflammatory Bowel

scholarly journals Discontinuation of Immunosuppressive Medications in Children With Inflammatory Bowel Disease on Combination Therapy

2020 ◽  
Vol 71 (6) ◽  
pp. 740-743
Author(s):  
Wael El-Matary ◽  
Matthew W. Carroll ◽  
Jennifer C. Debruyn ◽  
Hien Huynh ◽  
Eytan Wine ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Combination Therapy ◽  
Bowel Disease ◽  
Immunosuppressive Medications ◽  
Inflammatory Bowel

scholarly journals Young Woman with Leg Lesions

2021 ◽  
Vol 2 (5) ◽  
pp. 265-266
Author(s):  
Daniel Finnin
Keyword(s):  
Inflammatory Bowel Disease ◽  
Young Woman ◽  
Bowel Disease ◽  
Lower Leg ◽  
Skin Condition ◽  
Systemic Diseases ◽  
Case Presentation ◽  
Significant Pain ◽  
Immunosuppressive Medications ◽  
Inflammatory Bowel

Case Presentation: The patient was a 33-year-old woman with inflammatory bowel disease presenting for worsening lower leg lesions with significant pain recalcitrant to oral doxycycline. Discussion: Pyoderma gangrenosum is a rare ulcerative skin condition with significant pain that is often associated with other systemic diseases typically treated with immunosuppressive medications aimed at the underlying cause.

scholarly journals Prevalence and Incidence of Antimicrobial-Resistant Organisms among Hospitalized Inflammatory Bowel Disease Patients

2013 ◽  
Vol 24 (4) ◽  
pp. e117-e121 ◽  
Author(s):  
Alon Vaisman ◽  
Kevin Pivovarov ◽  
Allison McGeer ◽  
Barbara Willey ◽  
Bjug Borgundvaag ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Antibiotic Use ◽  
Time Interval ◽  
Methicillin Resistant ◽  
Extended Spectrum Beta Lactamase ◽  
Vancomycin Resistant Enterococci ◽  
Immunosuppressive Medications ◽  
Inflammatory Bowel ◽  
Vancomycin Resistant

BACKGROUND: Patients with inflammatory bowel disease (IBD) experience frequent hospitalizations and use of immunosuppressive medications, which may predispose them to colonization with antimicrobial-resistant organisms (ARO).OBJECTIVE: To determine the prevalence of ARO colonization on admission to hospital and the incidence of infection during hospitalization among hospitalized IBD patients.METHODS: A chart review comparing the prevalence of colonization and incidence of infection with methicillin-resistantStaphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producingEnterobacteriaceae(ESBL) in hospitalized IBD patients with those of non-IBD controls was performed.RESULTS: On admission, there were no significant differences between IBD inpatients and controls in the prevalence of colonization of methicillin-resistantS aureus(1.0% versus 1.2%; P=0.74), vancomycin-resistant enterococci (0.2% versus 0%; P=1.0) or ESBL (4.1% versus 5.5%; P=0.33). Pooling data from historical clinic-based cohorts, IBD patients were more likely than controls to have ESBL colonization (19% versus 6.6%; P<0.05). Antibiotic use on admission was associated with ESBL colonization among IBD inpatients (OR 4.2 [95% CI 1.4 to 12.6]). The incidence of ARO infections during hospitalization was not significantly different between IBD patients and controls. Among IBD patients who acquired ARO infections during hospitalizations, the mean time interval from admission to infection was shorter for those who were already colonized with ARO on admission.CONCLUSIONS: This particular population of hospitalized IBD patients was not shown to have a higher prevalence or incidence of ARO colonization or infection compared with non-IBD inpatients.

Sign in / Sign up

Export Citation Format

Share Document